Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy
Safety and Efficacy of Pegylated Recombinant Human Granulocyte-colony Stimulating Factor(PEG-rhG-CSF) in Preventing Neutropenia in Children With Tumor After Chemotherapy:A Multi-center, Single Arm Trial.
研究概览
详细说明
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Yizhuo Zhang
- 电话号码:020-87342459
- 邮箱:zhangyzh@sysucc.org.cn
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- 招聘中
- Sun Yat-sen University Cancer Center,
-
接触:
- Junting Huang, Dr
- 电话号码:+8613632483966
- 邮箱:huangjt@sysucc.org.cn
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 1)6 years < age < 18 years old, regardless of gender; 2)Tumor patients diagnosed by histopathology or bone marrow cytology; 3)Patients who have not been treated for the first time; 4)ECoG score ≤ 2; 5)The expected survival time is more than 8 months; 6)The hematopoietic function of bone marrow was normal (ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L, Hb ≥ 75 g / L, WBC ≥ 3.0 × 109 / L); 7)Receive high-intensity chemotherapy, such as scccg lymphoma, CAV / ie, VIP regimen, etc., and expect bone marrow suppression of grade III or above after chemotherapy.
8)Patient's parent or guardian signs informed consent.
Exclusion Criteria:
Patients with any of the following items will not be enrolled in this study:
- Local or systemic infection without adequate control;
- Severe visceral dysfunction;
- Liver function test: total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST) were all higher than 2.5 times of the upper limit of normal value; if due to liver metastasis, the above indicators were more than 5 times of the upper limit of normal value; renal function test: Serum creatinine (CR) > 2 times of the upper limit of normal value;
- Those who took the same kind of other tested drugs or accepted clinical trials of other drugs within 4 weeks before enrollment;
- Allergic to peg-rhG-CSF, rhG-CSF and other preparations or proteins expressed by Escherichia coli;
- Serious mental illness, affecting informed consent and / or expression or observation of adverse reactions;
- The researcher judged the patients who were not suitable to participate.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:PEG-rhG-CSF
pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection
|
The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
safety of PEG-rhG-CSF in the prevention of neutropenia in children with tumor after chemotherapy
大体时间:From the beginning of observation to the end of observation(6 weeks) of the last enrolled patient
|
The incidence and severity of adverse events;
|
From the beginning of observation to the end of observation(6 weeks) of the last enrolled patient
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
To evaluate the effectiveness of PEG-rhG-CSF in preventing neutropenia in children with tumor after chemotherapy.
大体时间:From the beginning of observation to the end of observation(6 weeks) of the last enrolled patient
|
The incidence of grade III / IV ANC reduction in each chemotherapy cycle
|
From the beginning of observation to the end of observation(6 weeks) of the last enrolled patient
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.